Fig. 1
From: Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
a Differences in survival during the follow-up in noninvasively ventilated patients treated and not treated with TCZ (log-rank p value = 0.0057). b Differences in survival during the follow-up between patients treated with IV or SC TCZ, or not treated with TCZ. No significant differences were found between SC and IV TCZ -treated patients (log-rank p value = 0.092), and the differences between IV TCZ-treated and untreated patients was significant (log-rank p value = 0.0017), but not the difference between SC TCZ-treated and untreated patients (log-rank p value = 0.53)